Acorda Therapeutics Inc. (NASDAQ: ACOR) is -66.17% lower on its value in year-to-date trading and has touched a low of $0.42 and a high of $2.77 in the current 52-week trading range. The ACOR stock was last observed hovering at around $0.71 in the last trading session, with the day’s loss setting it -0.02% off its average median price target of $1.00 for the next 12 months. It is also 86.2% off the consensus price target high of $5.00 offered by 3 analysts, but current levels are 31.0% higher than the price target low of $1.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $0.69, the stock is -7.85% and -13.42% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 12.6 million and changing -2.80% at the moment leaves the stock -10.07% off its SMA200. ACOR registered -64.79% loss for a year compared to 6-month loss of -5.96%. The firm has a 50-day simple moving average (SMA 50) of $0.7384 and a 200-day simple moving average (SMA200) of $0.7042.
The stock witnessed a 6.76% gain in the last 1 month and extending the period to 3 months gives it a 32.71%, and is -8.17% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.23% over the week and 10.72% over the month.
Acorda Therapeutics Inc. (ACOR) has around 344 employees, a market worth around $34.10M and $165.30M in sales. Current P/E ratio is 0.75. Profit margin for the company is 29.70%. Distance from 52-week low is 63.38% and -75.09% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.20%).
Acorda Therapeutics Inc. (ACOR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Acorda Therapeutics Inc. (ACOR) is a “Overweight”. 3 analysts offering their recommendations for the stock have an average rating of 2.70, where 2 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Acorda Therapeutics Inc. is expected to release its quarterly report on 05/06/2021 and quarterly earnings per share for the current quarter are estimated at -$0.52 with sales reaching $25.86M over the same period.The EPS is expected to grow by 6.40% this year, but quarterly earnings will post -26.90% year-over-year. Quarterly sales are estimated to shrink -48.80% in year-over-year returns.
Acorda Therapeutics Inc. (ACOR) Top Institutional Holders
The shares outstanding are 47.71M, and float is at 47.15M with Short Float at 5.54%.
The top institutional shareholder in the company is Renaissance Technologies, LLC with over 3.84 million shares valued at $11.86 million. The investor’s holdings represent 8.00% of the ACOR Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 2.86 million shares valued at $8.84 million to account for 5.97% of the shares outstanding. The other top investors are Point72 Asset Management, L.P. which holds 2.0 million shares representing 4.17% and valued at over $6.18 million, while Acadian Asset Management holds 3.83% of the shares totaling 1.84 million with a market value of $5.67 million.
Acorda Therapeutics Inc. (ACOR): Who are the competitors?
The company’s main competitors (and peers) include BioMarin Pharmaceutical Inc. (BMRN) that is trading 4.34% up over the past 12 months. Short interest in the company’s stock has fallen -107.22% from the last report on Nov 12, 2020 to stand at a total of 0.9 million short shares sold with a short interest ratio of 0.76.